Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neural Markers of Aggression and Irritability to Predict CNS Stimulant Response in ADHD
NCT06871488Phase 4Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Mar 2026
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Affective Reactivity Index at 14 days, ADHD Rating Scale 5 up to 12 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06871488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871488.